APLT Profile
Applied Therapeutics Inc (APLT) is a clinical-stage biopharmaceutical company that focuses on developing treatments for a range of diseases caused by dysregulated metabolism. The company's lead drug candidate, AT-007, is being developed to treat Galactosemia, a rare genetic disorder. Applied Therapeutics is also developing other product candidates for diabetic complications, diabetic cardiomyopathy, and other metabolic diseases.
APLT's pipeline includes multiple drug candidates that target a variety of metabolic pathways. The company's product candidates use proprietary technology to modulate pathways involved in metabolism, including the aldose reductase pathway, the hexosamine biosynthesis pathway, and the advanced glycation end-product pathway. Applied Therapeutics is developing product candidates that target these pathways in order to treat diseases such as diabetic cardiomyopathy, diabetic peripheral neuropathy, and diabetic nephropathy.
Applied Therapeutics was founded in 2016 and is headquartered in New York City. The company's management team includes individuals with extensive experience in drug development and clinical research. Applied Therapeutics has partnerships with multiple academic institutions and is backed by prominent venture capital firms.
As of September 2021, APLT's market capitalization is approximately $655 million, and its stock is traded on the NASDAQ stock exchange.
|
